| Name | Ruzotolimod |
|---|
| Description | Ruzotolimod is the agonist of TLR7. Ruzotolimod has the potential for the research of HBV, COVID-19 or SARS-CoV-2 infection (extracted from patent WO2021130195A1)[1]. |
|---|---|
| Related Catalog | |
| Target |
TLR7[1] |
| References |
[1]. Qingyan BO, et al. Method of treating virus infection using a tlr7 agonist. Patent WO2021130195A1. |
| Molecular Formula | C14H18N4O5S |
|---|---|
| Molecular Weight | 354.38 |